Kyverna Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KYTX Nasdaq 2830 kyvernatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kyverna Therapeutics, Inc.

Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity - Dec 15th, 2025 4:40 pm
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock - Dec 15th, 2025 2:01 pm
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome - Dec 15th, 2025 4:30 am
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease - Dec 15th, 2025 1:41 am
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - Dec 14th, 2025 12:30 pm
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Dec 12th, 2025 5:30 am
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - Nov 12th, 2025 2:05 pm
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference - Nov 10th, 2025 6:00 am
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - Nov 3rd, 2025 6:00 am
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - Oct 29th, 2025 4:30 am
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 - Oct 25th, 2025 9:00 am
Kyverna Therapeutics, Inc.'s (NASDAQ:KYTX) top owners are private equity firms with 36% stake, while 26% is held by individual investors - Oct 22nd, 2025 10:39 am
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Oct 22nd, 2025 6:00 am
Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout - Oct 17th, 2025 7:59 am
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - Sep 24th, 2025 7:05 am
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - Sep 15th, 2025 11:02 am
3 Promising Penny Stocks With Market Caps Under $2B - Sep 10th, 2025 6:05 am
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event - Aug 28th, 2025 6:00 am
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September - Aug 25th, 2025 2:02 pm
Here's Why Kyverna Therapeutics (NASDAQ:KYTX) Must Use Its Cash Wisely - Aug 21st, 2025 4:07 am